Last reviewed · How we verify
Fibrate treatment
Fibrate treatment is a Small molecule drug developed by Maastricht University Medical Center. It is currently FDA-approved.
Fibrate treatment, marketed by Maastricht University Medical Center, holds a position in the lipid management market with a key composition patent expiring in 2028. The drug's key strength lies in its established market presence and ongoing patent protection. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Fibrate treatment |
|---|---|
| Sponsor | Maastricht University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis (NA)
- Liraglutide Effect in Atrial Fibrillation (PHASE4)
- COAST Study - Cholesterol Optimization After Stroke
- Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation (PHASE2)
- Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO) (NA)
- Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry
- Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis (PHASE2)
- Fenofibrate in Ulcerative Colitis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fibrate treatment CI brief — competitive landscape report
- Fibrate treatment updates RSS · CI watch RSS
- Maastricht University Medical Center portfolio CI
Frequently asked questions about Fibrate treatment
What is Fibrate treatment?
Who makes Fibrate treatment?
What development phase is Fibrate treatment in?
Related
- Manufacturer: Maastricht University Medical Center — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing